← Back to Search

Other

VOY-101 for Age-Related Macular Degeneration

Phase 1 & 2

Waitlist Available

Research Sponsored by Perceive Biotherapeutics, Inc.

Eligibility Criteria Checklist

Specific guidelines that determine who can or cannot participate in a clinical trial

Must have

Well-demarcated GA secondary to AMD in the absence of MNV and in the absence of history of MNV.

Are ≥50 years of age at the time of consent.

Timeline

Screening 3 weeks

Treatment Varies

Follow Up through 24 months

Awards & highlights

Study Summary

This trialtests a drug to see if it's safe and works. Subjects will get different doses; some a drug, some a placebo.

Who is the study for?

This trial is for individuals over 50 with advanced non-neovascular age-related macular degeneration (AMD). Participants must be able to understand the study, provide consent, and commit to follow-up visits. They should have a specific form of AMD without signs of certain complications and meet genetic risk criteria.Check my eligibility

What is being tested?

The study tests VOY-101 in patients with AMD. It starts by finding the highest dose people can tolerate without too many side effects (dose escalation), then compares that dose to a lower one and a control group to see which works best.See study design

What are the potential side effects?

While specific side effects are not listed here, typical ones from similar eye treatments may include discomfort at the injection site, increased eye pressure, inflammation inside the eye, bleeding or infection risks.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

Select...

I have advanced AMD without any signs of MNV.

Select...

I am 50 years old or older.

Select...

My genetic test shows I'm at risk for AMD.

Timeline

Screening ~ 3 weeks3 visits

Treatment ~ Varies

Follow Up ~ through 24 months

Screening ~ 3 weeks

Treatment ~ Varies

Follow Up ~through 24 months

This trial's timeline: 3 weeks for screening, Varies for treatment, and through 24 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.

Primary outcome measures

Safety Endpoints

Trial Design

3Treatment groups

Experimental Treatment

Group I: Mid DoseExperimental Treatment1 Intervention

VOY-101 Mid Dose (single dose, IVT)

Group II: Low DoseExperimental Treatment1 Intervention

VOY-101 Low Dose (single dose, IVT)

Group III: High DoseExperimental Treatment1 Intervention

VOY-101 High Dose (single dose, IVT)

0 / 3Eligibility criteria met

Find a Location

Who is running the clinical trial?

Perceive Biotherapeutics, Inc.Lead Sponsor

1 Previous Clinical Trials

140 Total Patients Enrolled

Media Library

VOY-101 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05380492 — Phase 1 & 2

Age-Related Macular Degeneration Research Study Groups: Low Dose, Mid Dose, High Dose

Age-Related Macular Degeneration Clinical Trial 2023: VOY-101 Highlights & Side Effects. Trial Name: NCT05380492 — Phase 1 & 2

VOY-101 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05380492 — Phase 1 & 2

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

How many volunteers are participating in this research endeavor?

"Yes, the clinicaltrials.gov page for this trial confirms that recruitment is ongoing; with 45 patients being sought from a single medical centre since November 17th 2022."

Answered by AI

Is this trial actively seeking participants?

"Results published on clinicaltrials.gov report that this research is actively seeking participants, with the first listing having been posted and updated on November 17th 2022."

Answered by AI

Recent research and studies

clinicaltrials.govStudy

Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration

2022. "Study of VOY-101 in Patients With Advanced Non-Neovascular Age-Related Macular Degeneration". ClinicalTrials.gov. https://clinicaltrials.gov/ct2/show/NCT05380492.